Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3135-3172
Closed Access | Times Cited: 18

Showing 18 citing articles:

A partial epithelial‐mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction
Gil A Pastorino, Ilir Sheraj, K Huebner, et al.
The Journal of Pathology (2024) Vol. 262, Iss. 3, pp. 347-361
Open Access | Times Cited: 8
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
Debasis Das, Lingzhi Xie, Hong Jian
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 6
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188927-188927
Closed Access | Times Cited: 19
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation
Yasheng Zhu, Xiuquan Ye, Yuxing Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7283-7300
Closed Access | Times Cited: 5
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo
Xudong Pang, Dawei Cui, Binhua Lv, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1563-1579
Closed Access | Times Cited: 4
Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy
Mehlika Dilek Altıntop, İpek Ertorun, Gülşen Akalın Çiftçi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116698-116698
Closed Access | Times Cited: 4
Design and Efficient Synthesis of New 4-Amino Substituted 2-(4-bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines of Anticancer Interest and their In Silico Study
Raj Kumar, Sahil Arora, Shikha Thakur, et al.
Synthesis (2024)
Closed Access | Times Cited: 3
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
Pengyun Li, Bingkun Li, Ning Yang, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 7-8, pp. 477-492
Closed Access | Times Cited: 5
Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)
Bhatu R. Patil, Kunal V. Bhadane, Iqrar Ahmad, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 109, pp. 117796-117796
Closed Access | Times Cited: 1
Exploring the potential mechanism of ginsenoside Rg1 to regulate ferroptosis in Alzheimer's disease based on network pharmacology
Xu Deng, Zixiong Qiu, Xiaoshuai Chen, et al.
European Journal of Pharmacology (2024) Vol. 979, pp. 176859-176859
Closed Access | Times Cited: 1
Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors
Qiangfeng Wang, Yumeng Zhu, Junping Pei
Future Medicinal Chemistry (2024) Vol. 16, Iss. 18, pp. 1923-1944
Closed Access | Times Cited: 1
Design, Synthesis, and Anticancer Evaluation of Hemithioindigos via Inhibition of Human Topoisomerases
Manpreet Kaur, Prabhat Suman, Sahil Arora, et al.
ChemistrySelect (2023) Vol. 8, Iss. 41
Closed Access | Times Cited: 3
Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
Vehary Sakanyan, Nina Iradyan, Rodolphe Alves de Sousa
BioTech (2023) Vol. 12, Iss. 3, pp. 57-57
Open Access | Times Cited: 2
Transforming cancer care: Immunotherapy with advanced drug delivery
Saurabh Srivastava, Ching Siang Tan, Deviga Kaliyappan, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 96, pp. 105670-105670
Closed Access
Design, synthesis, and anticancer assessment of structural analogues of (E)-1-((3,4,5-trimethoxybenzylidene)amino)-4-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]quinoxaline-2-carbonitrile (6b), an imidazo[1,2-a]quinoxaline-based non-covalent EGFR inhibitor
Manvendra Kumar, Kiran T. Patil, Pritam Maity, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 7, pp. 2322-2339
Closed Access
Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker
Vladimir A. Brylev, Ekaterina V. Ryabukhina, Evgeniya V. Nazarova, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1434-1434
Open Access
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
Defa Wu, Qian Sun, Hongjun Tang, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101176-101176
Closed Access
In silico construction and evaluation of anti-EGFR ScFv and IFN-β fusion protein as a novel immunocytokine for the treatment of HER1 positive breast cancer
Muhammad Islam Khan, Muhammad Hassan, Aamir Sohail, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top